Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA's Generic Research May Include EpiPen And Competitors

Executive Summary

Agency wants to acquire Auvi-Q and authorized generics for EpiPen and Adrenaclick, potentially for research on whether user interface affects substitutability.


Related Content

US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?
Generic Industry Wants US FDA To Advance Research To Eliminate Need For Clinical BE Studies
US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs
ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines
Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology
Generic Combination Products May Be Permitted Delivery Device Variations
Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff
Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
EpiPen Familiarity May Prove Tough Hurdle For Generics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts